Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Pierson

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Brain : a Journal of Neurology|October 7, 2010
Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopmentPeggy C Nopoulos, Elizabeth H Aylward, Christopher A Ross, et al.
American Journal of Hematology|July 15, 2021
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman diseaseYoshito Nishimura, David C Fajgenbaum, Sheila K Pierson, et al.
BMC Genomics|July 1, 2011
Complete genome sequence of the filamentous anoxygenic phototrophic bacterium Chloroflexus aurantiacusKuo-Hsiang Tang, Kerrie Barry, Olga Chertkov, et al.
Blood Advances|September 1, 2023
Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomesSheila K Pierson, Megan S Lim, Gordan Srkalovic, et al.
JCI Insight|May 8, 2020
Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman diseaseRuth-Anne Langan Pai, Alberto Sada Japp, Michael Gonzalez, et al.
Blood|March 25, 2020
Increased mTOR activation in idiopathic multicentric Castleman diseaseDaniel J Arenas, Katherine Floess, Dale Kobrin, et al.
Infectious Diseases and Therapy|May 29, 2020
Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic ReviewDavid C Fajgenbaum, Johnson S Khor, Alexander Gorzewski, et al.
Blood Advances|August 26, 2021
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman diseaseSheila K Pierson, Sushila Shenoy, Ana B Oromendia, et al.
The Journal of Clinical Investigation|August 14, 2019
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, Ruth-Anne Langan, Alberto Sada Japp, et al.
Blood Advances|February 14, 2025
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registrySheila K Pierson, Joshua D Brandstadter, Drew A Torigian, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Brain : a Journal of Neurology|October 7, 2010
Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopmentPeggy C Nopoulos, Elizabeth H Aylward, Christopher A Ross, et al.
American Journal of Hematology|July 15, 2021
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman diseaseYoshito Nishimura, David C Fajgenbaum, Sheila K Pierson, et al.
BMC Genomics|July 1, 2011
Complete genome sequence of the filamentous anoxygenic phototrophic bacterium Chloroflexus aurantiacusKuo-Hsiang Tang, Kerrie Barry, Olga Chertkov, et al.
Blood Advances|September 1, 2023
Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomesSheila K Pierson, Megan S Lim, Gordan Srkalovic, et al.
JCI Insight|May 8, 2020
Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman diseaseRuth-Anne Langan Pai, Alberto Sada Japp, Michael Gonzalez, et al.
Blood|March 25, 2020
Increased mTOR activation in idiopathic multicentric Castleman diseaseDaniel J Arenas, Katherine Floess, Dale Kobrin, et al.
Infectious Diseases and Therapy|May 29, 2020
Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic ReviewDavid C Fajgenbaum, Johnson S Khor, Alexander Gorzewski, et al.
Blood Advances|August 26, 2021
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman diseaseSheila K Pierson, Sushila Shenoy, Ana B Oromendia, et al.
The Journal of Clinical Investigation|August 14, 2019
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, Ruth-Anne Langan, Alberto Sada Japp, et al.
Blood Advances|February 14, 2025
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registrySheila K Pierson, Joshua D Brandstadter, Drew A Torigian, et al.
Pageof 10